Evidence map›Paper›PMID 40131644›Full record

ArticleDiscover oncology2025

Applying integrated transcriptome and single-cell sequencing analysis to develop a prognostic signature based on M2-like tumor-associated macrophages for breast cancer.

Yanghaochen Xu, Peiyan Lin, Ye Zhu, Qing Zhang, Jinhong Zhou

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanghaochen Xu *Department of Bioinformatics, Hangzhou Juno Genomics Inc., Hangzhou, China.
Peiyan Lin *Department of Gynecology, Zhejiang Hospital, Hangzhou, China.
Ye ZhuDepartment of Bioinformatics, Hangzhou Juno Genomics Inc., Hangzhou, China.
Qing ZhangDepartment of Gynecology, Zhejiang Hospital, Hangzhou, China.
Jinhong ZhouDepartment of Gynecology, Zhejiang Hospital, Hangzhou, China. zhoujh2440@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundM2-like tumor-associated macrophages (M2-like TAMs) function crucially in the tumor microenvironment (TME) and cancer development. This study developed a prognostic signature based on M2-like TAM-related genes for breast cancer (BRCA) applying transcriptome and scRNA-seq analysis.

methodsTCGA-BRCA, GSE20685, and GSE176078 datasets were downloaded from UCSC xena and GEO databases. AUCell score of immune-related genes (IRGs) was calculated using R package. Genes related to M2-like TAMs were screened by WGCNA. Prognostic genes were further identified by univariate Cox and LASSO regression analyses to form a RiskScore model, which was validated in external dataset. Furthermore, a nomogram was established by integrating RiskScore and clinical characteristics, and correlation analysis between the RiskScore and TME or chemotherapeutic drugs was conducted. Finally, the mRNA expression levels of the key genes identified were verified using quantitative real time polymerase chain reaction (qRT-PCR).

resultsAs macrophages exhibited the highest AUCell score of IRGs in single-cell transcriptomic atlas of BRCA, the cells were further classified into Macrophages C1 and C2 subtypes, with the C1 subtype showing a high expression of M2 macrophage marker genes. ARHGAP26, RILP, KLRB1, CSTA, KLHDC7B, PSMB8, KYNU, RNASE1, LONRF3, and TRPM2 were screened as the prognostic signature genes from a total of 903 M2-like TAM-related genes to establish a robust RiskScore model. Furthermore, a nomogram with a strong predictive performance was constructed combining stage, Age, and RiskScore, and we found that most immune cells showed a negative correlation with RiskScore. Multiple drugs were closely associated with the RiskScore, notably, Ribociclib_1632 had higher a half-maximal inhibitory concentration (IC50) value in high-risk group. Finally, qRT-PCR demonstrated that the mRNA expression levels of the 10 genes were significantly different in control and BRCA cell lines.

conclusionWe identified 10 M2-like TAM-related prognostic signature genes for BRCA, providing potential therapeutic targets for the treatment of the cancer.

Indexed as

Breast cancerImmune-related genesM2 macrophagesPrognosisTherapeutic targetsTumor microenvironment

Identifiers

PMID40131644
PMCPMC11937466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.